Application

PP1 has been used as: an inhibitor of sarcoma (Src) family kinases (SFK) like hematopoietic cell kinase (hck) and fyn a selective Src tyrosine kinase inhibitor in hippocampal neuronal cultures to test its effect on neurite growth a Src-kinase blocker to test its effect on brimonidine (BMD)-induced phosphorylation in extracellular signal-activated kinases(ERK1/2)

Biochem/physiol Actions

PP1 is a pyrazolopyrimidine compound that acts as a competitive inhibitor of adenosine triphosphate (ATP) binding. It also inhibits protein tyrosine kinase (PTK6) and may be useful in the therapeutic management of PTK6 positive based breast cancer malignancy.

PP1 is a potent and selective Src family protein tyrosine kinase inhibitor.

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

5, 25 mg in glass bottle